ArticleiScience2026
Tumor-infiltrating lymphocytes display prognostic signatures associated with chemotherapy response in TNBC patients.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype often resistant to neoadjuvant chemotherapy (NAC), and tumor-infiltrating lymphocytes (TILs) are important predictors of response. Using single-cell RNA sequencing datasets of pre-treated TNBC tumors, we identified an 80-gene TIL-specific signature that captures immune activation and stratifies tumors by TIL abundance. Pathway analysis showed enrichment of immune-regulatory programs, including allograft rejection, consistent with adaptive immune activity. Validation across single-cell and bulk datasets linked the signature to favorable response and relapse-free survival. A multi-stage feature selection pipeline refined the panel to 30 genes, achieving strong prediction of pathological complete response versus residual disease across eleven independent TNBC cohorts (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.